Thus, more clinical samples are needed to clarify the specific clinical roles of CLDN10 in ccRCC, and more basic experiments are required to determine the specific mechanism of CLDN10 inhibiting ccRCC metastasis to provide important theoretical support for the exploitation of a novel kidney cancer therapeutic target. The gene discussed is CLDN10; the disease is nonpapillary renal cell carcinoma.